


## PHARMACEUTICAL 2021



Merck & Co. Inc. Rank 21 of 409







## PHARMACEUTICAL 2021



## Merck & Co. Inc. Rank 21 of 409



The relative strengths and weaknesses of Merck & Co. Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merck & Co. Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 364% points. The greatest weakness of Merck & Co. Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is 166%, being 520% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	27,764,000
Cost of Goods Sold	15,485,000
Intangible Assets	34,842,000
Liabilities, Current	27,327,000
Liabilities, Non-Current	0
Other Assets	10,996,000
Other Compr. Net Income	-456,000
Other Expenses	1,401,000
Other Liabilities	0
Other Net Income	0
Property and Equipment	17,986,000
Research and Development	13,558,000
Revenues	47,994,000
Selling, General and Administrative Expense	10,468,000

Output Variable	Value in 1000 USD
Assets	91,588,000
Liabilities	27,327,000
Expenses	40,912,000
Stockholders Equity	64,261,000
Net Income	7,082,000
Comprehensive Net Income	6,854,000
Economic Capital Ratio	166%